Hyperhomocysteinemia in heart transplantation: From bench to bedside

Journal of Heart and Lung Transplantation

Volumn 22, Issue 10, 2003, Pages 1069-1081

  Miriuka, Santiago G ^a,b   Delgado, Diego H ^a,b   Cole, David E C ^a   Rao, Vivek ^a,b   Ross, Heather J ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACID LIPASE; ALCOHOL; CAFFEINE; CARBAMAZEPINE; COLESTIPOL; CREATININE; CYANOCOBALAMIN; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; ENZYME; FIBRIN; FIBRINOGEN; FOLIC ACID; FREE RADICAL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; METHIONINE; METHOTREXATE; NICOTINIC ACID; NITRIC OXIDE; PHENYTOIN; PLACEBO; PYRIDOXINE; THEOPHYLLINE; TRIACYLGLYCEROL; TRIMETHOPRIM;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FOOD INTAKE; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEART GRAFT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART TRANSPLANTATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; KIDNEY FAILURE; METABOLISM; MORTALITY; NEPHROTOXICITY; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL REQUIREMENT; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECIPIENT; REOPERATION; REVIEW; SUPPLEMENTATION; THROMBOSIS; VITAMIN DEFICIENCY;

EID: 0141433276     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)01153-1     Document Type: Article

References (88)

1. Ambrosi P., Garçon D., Riberi A., et al. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis. 138:1998;347-350.
2. Miner S.E.S., Cole D.E.C., Evrovski J., Verma A., Daly P.A., Ross H.J. Hyperhomocysteinemia and transplant coronary artery disease in cardiac transplant recipients. Clin Transplant. 15:2001;258-262.
3. Finkelstein J.D. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 26:(3):2000;219-225.
4. Langman L, Cole D. Homocysteine. Critical reviews in clinical laboratory sciences. 1999;36(4):365-406.
5. Fowler B. The folate cycle and disease in humans. Kidney Int. 59:(suppl78):2001;S221-229.
6. Födinger M., Wagner O.F., Hörl W.H., Sunder-Plassman G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int. 59:(78):2001;S238-242.
7. Boers G.H., Smals A.G., Trijbels F.J., et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Eng J Med. 313:1985;709-715.
8. Ma J., Stampfer M.J., Hennekens C.H., et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
9. van Bockxmeer F.M., Mamotte C.D., Vasikaran S.D., Taylor R.R. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.
10. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost. 26:(3):2000;255-261.
11. Potena L., Grigioni F., Viggiani M., et al. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C→T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. J Heart Lung Transplant. 20:2001;1245-1251.
12. Pethig K., Hoffmann A., Heublein B., Timke A., Gross C., Haverich A. Cardiac allograft vascular disease after orthotopic heart transplantation methylene-tetrahydrofolate reductase gene polymorphism C677T does not account for rapid progressive form . Transplantation. 69:(3):2000;442-445.
13. Elstein E., Huan C., Fitchett M., Cantarovitch M., Marpole D. C677T gene mutation in methyltetrahydrofolate reductase as a risk factor for cardiac allograft vasculopathy. Transplant Proc. 31:1999;99.
14. Schneede J., Refsum H., Ueland P.M. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost. 26:(3):2000;263-279.
15. Boers G.H.J. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Throm Hemost. 26:(3):2000;291-295.
16. van Guldener C., Stam F., Stehouwer D.A. Homocysteine metabolism in renal failure. Kidney Int. 59:(suppl78):2001;S234-237.
17. van Guldener C., Robinson K. Homocysteine and renal disease. Semin Thromb Hemost. 26:(3):2000;313-324.
18. Stein G., Müller A., Busch M., Fleck C., Sperschneider H. Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. Kidney Int. 59:(suppl78):2001;S262-265.
19. Cole D., Ross H., Evroski J., et al. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem. 44:(11):1998;2307-2312.
20. Ignatescu M., Födiger M., Kletzmayr J., et al. Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells. Kidney Int. 59:(suppl78):2001;S258-261.
21. Ambrosi P., Barlatier A., Habib G., et al. Hyperhomocysteinemia in heart transplant patients. Eur Heart J. 15:1994;191-195.
22. Berger P., Jones J.D., Olson L.J., et al. Increase in total plasma homocysteine concentrations after cardiac transplantation. Mayo Clin Proc. 70:1995;125-131.
23. 6 concentrations prevalent risk factors for vascular disease in heart transplant recipients . Transplantation. 65:1998;544-550.
24. Cook R.C., Tupper J.K., Parker S., et al. Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. J Heart Lung Transplant. 18:1999;420-424.
25. Parisi F., Kost-Byerly S., Saponara I., Di Donato R., Di Liso G. Elevated plasma homocysteine concentrations after pediatric heart transplantation. Transpl Int. 13:(suppl1):2000;S235-239.
26. Thambyrajah J., Towned J.N. Homocysteine and atherothrombosis - mechanisms for injury. Eur Heart J. 21:2000;967-974.
27. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med. 338:(15):1998;1042-1050.
28. Jakubowski H. Homocysteine thiolactone metabolic origin and protein homocysteinylation in humans . J Nutr. 130:2000;377S-381S.
29. Jakubowski H., Zhang L., Bardeguez A., Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells Implication for atherosclerosis . Circ Res. 87:2000;45-51.
30. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. J Biol Chem. 272:(3):1997;1935-1942.
31. Olszewski A.J., McCully K.S. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med. 14:1993;683-693.
32. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
33. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98:1996;5-7.
34. Blom H.J. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost. 26:(3):2000;227-232.
35. Chambers J.C., Ueland P.M., Wright M., Doré C.J., Refsum H., Kooner J.S. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ Res. 89:2001;187-192.
36. Ungvari Z., Pacher P., Rischák K., Szollár L., Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Artherioscler Thromb Vasc Biol. 19:1999;1899-1904.
37. Zhang X., Li H., Jin H., Ebin Z., Brodsky S., Goligorsky M.S. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol. 279:2000;F671-678.
38. Maxwell S.R.J. Coronary artery disease - free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol. 95:(supplI):2000;I65-71.
39. Upchurch G.R. Jr, Welch G.N., Fabian A.J., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 272:(27):1997;17012-17017.
40. Holvoet P., van Cleemput J., Collen D., Vanhaecke J. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscl Thromb Vasc Biol. 20:2000;698-702.
41. Doshi S.N., Goodfellow J., Lewis M.J., McDowell I.F.W. Homocysteine and endothelial function. Cardiovasc Res. 42:1999;578-582.
42. Davis S.F., Yeung A.C., Meredith I.T., et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post-transplant. Circulation. 93:1996;457-462.
43. Hollenberg S.M., Klein L.W., Parrillo J.E., et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. 104:(25):2001;3091-3096.
44. Mattias D., Becker C.H., Riezler R., Kindling P.H. Homocysteine induced atherosclerosis-like alterations of the aorta in normotensive and hypertensive rats following the application of high doses of methionine. Atherosclerosis. 122:1996;201-216.
45. van Guldener C., Stehouwer C.D.A. Hyperhomocysteinemia, vascular pathology and endothelial dysfunction. Semin Thromb Hemost. 26:(3):2000;281-289.
46. Collins T., Cybulsky M. NF-κB pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 107:(3):2001;255.
47. Gross P.L., Aird W.C. The endothelium and thrombosis. Semin Thromb Hemost. 26:(5):2000;463-478.
48. Lentz S., Sobey C.G., Piegors D.J., Bhopatkar M.Y., Faraci F.M., Malinow M.R. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 93:(1):1996;24-29.
49. Coppola A., Davi G., De Stefano V., Mancini F.P., Cerbone A.M., Di Minno G. Homocysteine, coagulation, platelet function and thrombosis. Semin Thromb Hemost. 26:(3):2000;243-254.
50. Davi G., Di Minno G., Coppola A., et al. Oxidative stress and platelet activation in homozygous homocysteinuria. Circulation. 104:2001;1124-1128.
51. Labarrere C.A. Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation. Curr Opin Cardiol. 14:1999;133-139.
52. Hoffman M.A., Lalla E., Lu Y., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 107:2001;675-683.
53. Zhou J., Møller J., Danielsen C.C., et al. Dietary supplementation with methionine promotes early atherosclerosis but not plaque rupture in Apo E-deficient mice. Arterioscler Thromb Vasc Biol. 21:2001;1470-1476.
54. Preufer D., Scalia R., Lefer A.M. Homocysteine provokes leukocyte-endothelium interaction by down regulation of nitric oxide. Gen Pharmacol. 33:1999;487-498.
55. Dudman N., Temple S.E., Guo X.G., Fu W., Perry M.A. Homocysteine enhances neutrophil-endothelial interactions in both cultured humans cells and rats in vivo. Circ Res. 84:1999;409-416.
56. Lubec B., Labudova O., Hoeger H., et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation. 94:1996;2620-2625.
57. Hoit B. Two faces of nitric oxide. Circ Res. 89:2001;289-291.
58. Jourdheuil-Rahmani D., Rolland P., Rosset E., Branchereau S., Garçon D. Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovasc Res. 34:1997;597-602.
59. Nygård O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med. 337:1997;230-236.
60. Lowering blood homocysteine with folic acid based supplements meta-analysis of randomized trials . BMJ. 316:1998;894-898.
61. Clarke R., Armitage J. Vitamin supplements and cardiovascular risk review of the randomized clinical trials of homocysteine-lowering vitamin supplements . Semin Thromb Hemost. 26:(3):2000;341-348.
62. Jacques P.F., Selhub J., Bostom A.G., Wilson P.W.F., Rosenberg I.H. The effects of folic acid fortification on plasma folate and total homocysteine concentrations. N Eng J Med. 340:1999;1449-1454.
63. Law M. Fortifying food with folic acid. Semin Thromb Hemost. 26:(3):2000;349-352.
64. Tice J.A., Ross E., Coxson P.G., et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary artery disease. JAMA. 286:(8):2001;936-943.
65. Bostom A.G., Shemin D., Gohh R.Y., et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant patients. Kidney Int. 59:(suppl78):2001;S246-252.
66. Miner S.E.S., Cole D.E.C., Evrovski J., et al. Pyridoxine improves endothelial function in cardiac transplant recipients. J Heart Lung Transplant. 20:2001;964-969.
67. Cook R.C., Parker S., Kingsbury K., et al. Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. J Heart Lung Transplant. 20:2001;310-315.
68. Potena L., Grigioni F., Magnani G., et al. Increasing plasma homocysteine during follow-up in heart transplant recipients effects of folate and renal function . Ital Heart J. 1:(5):2000;344-348.
69. Kutschka I., Pethig K., Strüber M., Dieterich C., Harringer W., Haverich A. Homocysteine - a treatable risk factor for allograft vascular disease after heart transplantation? J Heart Lung Transplant. 20:2001;743-746.
70. Yap S., Naughten E.R., Wilcken B., Wilcken D.E.L., Boers G.H.J. Vascular complications of severe hyperhomocysteinemia in patients with homocysteinuria due to cystathionine β-synthase deficiency effects of homocysteine lowering therapy . Semin Thromb Hemost. 26:(3):2000;335-340.
71. Boers G.H.J., Smals A.G.H., Trijbels F.J.M., et al. Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Eng J Med. 313:1985;709-715.
72. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia an independent risk factor for vascular disease . N Eng J Med. 324:1991;1149-1155.
73. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
74. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 274:1995;1049-1057.
75. Weis M., von Scheidt W. Cardiac allograft vasculopathy a review . Circulation. 96:1997;2069-2077.
76. Andersen H.O. Heart allograft vascular disease an obliterative vascular disease in transplanted hearts . Atherosclerosis. 142:1999;243-263.
77. Johnson M.R. Transplant coronary disease nonimmunologic risk factors . J Heart Lung Transplant. 11:1992;S124-132.
78. Constanzo M.R. Cardiac allograft vasculopathy relationship with acute cellular rejection and histocompatibility . J Heart Lung Transplant. 11:1992;S90-103.
79. Labarrere C.A., Nelson D.R., Miller S.J., et al. Value of serumsoluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, post-transplant ischemic events, and cardiac graft failure. Circulation. 102:2000;1549-1555.
80. Labarrere C.A., Nelson D.R., Park J.W. Pathologic markers of allograft arteriopathy insight into the pathophysiology of cardiac allograft chronic rejection . Curr Opin Cardiol. 16:2001;110-117.
81. Orosz C.G. Considerations regarding the contributions of B cells to chronic allograft rejection in experimental animal models. J Heart Lung Transplant. 19:2000;634-637.
82. Jurcevic S., Ainsworth M.E., Pomerance A., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation. 71:2001;886-892.
83. Gullestad L., Simonsen S., Ueland T., et al. Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol. 84:1999;999-1003.
84. Perrault L., Mahlberg F., Breugnot C., et al. Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplant. Arterioscler Thromb Vasc Biol. 20:2000;728-736.
85. Hoogeveen E.K., Kostense P.J., Jakobs C., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes. Circulation. 101:2000;1506-1511.
86. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease a serial intravascular ultrasound study . J Am Coll Cardiol. 38:2001;206-213.
87. Cooke G.E., Eaton G.M., Whitby G., et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol. 36:2000;509-516.
88. Giannetti N., Herity N.A., Alimollah A., et al. Mild hyperhomocysteinemia is not associated with cardiac allograft coronary disease. Clin Transplant. 15:2001;247-252.